BiotechTube

CP-866,087

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alcoholism

Conditions

Alcoholism

Trial Timeline

Dec 1, 2003 → Dec 1, 2004

NCT ID
NCT00147576

About CP-866,087

CP-866,087 is a phase 2 stage product being developed by Pfizer for Alcoholism. The current trial status is completed. This product is registered under clinical trial identifier NCT00147576. Target conditions include Alcoholism.

What happened to similar drugs?

4 of 9 similar drugs in Alcoholism were approved

Approved (4) Terminated (1) Active (4)
✅Seroquel XRAstraZenecaApproved
✅Acamprosate or NaltrexoneMerckApproved
✅Acamprosate + PlaceboMerckApproved
✅LevetiracetamUCBApproved
🔄Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy + Naltrexone 50 mg/day + Cognitive Behavioral Therapy + Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
❌Medisorb naltrexone 380 mg + Oral naltrexone to Medisorb naltrexone 380 mgAlkermesPhase 3
🔄Medisorb naltrexone 380 mg + Medisorb naltrexone 190 mgAlkermesPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00147576Phase 2Completed

Competing Products

18 competing products in Alcoholism

See all competitors
ProductCompanyStageHype Score
acamprosateJohnson & JohnsonPre-clinical
26
Topiramate and NaltrexoneJohnson & JohnsonPhase 1
29
TopiramateJohnson & JohnsonPhase 2
35
ondansetron + cognitive behavioral therapy + topiramate + cognitive behavioral therapy + Placebo + cognitive behavioral therapy + ondansetron + topiramate + cognitive behavioral therapyJohnson & JohnsonPhase 2
31
Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy + Naltrexone 50 mg/day + Cognitive Behavioral Therapy + Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
40
topiramateJohnson & JohnsonPhase 2
35
Seroquel XRAstraZenecaApproved
43
Quetiapine fumarateAstraZenecaPhase 2
35
Acamprosate or NaltrexoneMerckApproved
43
Acamprosate + PlaceboMerckApproved
43
SCH 900435 + PlaceboMerckPhase 2
27
LevetiracetamUCBApproved
43
levetiracetamUCBPhase 2
35
Nalmefene + PlaceboLundbeckPhase 1
18
Medisorb naltrexone 380 mg + Oral naltrexone to Medisorb naltrexone 380 mgAlkermesPhase 3
29
Medisorb naltrexone 380 mg + Medisorb naltrexone 190 mgAlkermesPhase 3
37
Medisorb naltrexone 380 mg + Oral naltrexone 50 mgAlkermesPhase 3
37
Medisorb naltrexone 190 mg + Medisorb naltrexone 380 mg + Placebo matching Medisorb naltrexone 190 mg + Placebo matching Medisorb naltrexone 380 mgAlkermesPhase 3
37